The French pharmaceutical industry association, the SNIP, has returnedto the attack on what it regards as the lack of reimbursable drug coverage for key areas of patient care in the country's health service.
The analysis of 18 medical conditions in the recent JNB-ACE study, published by the SNIP and International Research Labs (Marketletter May 28), showed that a considerable range of medical needs were not covered, or were covered inadequately, it says. Also, structural factors such as the aging of the population, increased birth rate and nutritional and environmental factors are set to increase those needs considerably.
The annual drug spending rate of growth required to meet those needs is 7%, says the SNIP, but French drug policy simply does not account for this. Last year's growth target was 2%, less than the 2.5% target for the reimbursable health service budget as a whole, and for 2001 it is 3%, against the more general target of 3.5%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze